ArticleProceedings of the National Academy of Sciences of the United States of America2026
WWOX maintains epidermal identity and suppresses EMT to prevent aggressive cutaneous squamous cell carcinoma.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- WWOX maintains epidermal identity and suppresses EMT to prevent aggressive cutaneous squamous cell carcinoma.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Cutaneous squamous cell carcinoma (cSCC), the second most common skin cancer, remains a major health burden worldwide. The WW domain-containing oxidoreductase (WWOX) is frequently altered in cancer; however, its role in epidermal biology and skin carcinogenesis remains undefined. Here, we uncover an essential function for WWOX in safeguarding epithelial identity and restraining cSCC progression. Using conditional knockout mice, we demonstrate that WWOX loss accelerates p53-driven cSCC, resulting in early, highly penetrant, and poorly differentiated tumors. Transcriptomic profiling revealed that WWOX deficiency drives epithelial-to-mesenchymal transition (EMT) and transcriptional plasticity, hallmarks of aggressive disease. Mechanistically, proximity ligation assays together with biochemical and cellular analyses support a close association between WWOX and p63 and imply that WWOX contributes to p63 stabilization; loss of WWOX reduces p63 protein levels and diminishes its binding to epithelial target genes, thereby disrupting epidermal transcriptional programs. Human tissue microarrays confirmed a concordant reduction of WWOX and p63 in advanced cSCC, correlating with poor differentiation. Functional assays in human keratinocytes and cSCC cells further showed that WWOX depletion enhances EMT plasticity, invasiveness, and metastatic colonization. Together, these findings identify WWOX as a critical regulator of epidermal integrity and reveal a previously unrecognized WWOX-p63 axis that constrains EMT and tumor progression in cSCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.